A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

Stopped The double-blind primary endpoint was not met. Open Label Extension period halted as a result.

Conditions

• Alopecia Areata

Interventions

• DRUG: ATI-50002 high dose
• DRUG: ATI-50002 low dose
• DRUG: Placebo

Sponsor

Aclaris Therapeutics, Inc.